Our industry-recognized Education team is committed to sharing program findings, best practices, insights, and trends from our educational programs across a range of therapeutic areas. These findings are regularly published in peer-reviewed journals, as well as presented at medical, patient, and industry conferences.
Targeted therapies have allowed for better management of neuroendocrine tumors (NETs), yet this requires that healthcare providers glean new knowledge about treatment options such as somatostatin analogs. To improve provider competency and include consideration of patient perspectives in treatment selection, PlatformQ Health and Healing NET Foundation teamed up with the...
Patients often face an epic journey of many years before receiving a diagnosis for a rare disease. With nearly one in 10 Americans impacted by a rare condition, it is essential that we decrease the time to diagnosis to improve the lives of these individuals and their families. To that...
ASCO Quality Care Symposium 2022: Patient Voice Helps Improve Point-of-Care for Urothelial Carcinoma
Targeted therapies such as immune checkpoint inhibitors are poised to improve long-term survival of patients with urothelial carcinoma. The emergence of these new therapies, however, presents knowledge gaps for clinicians, prompting PlatformQ Health and the Bladder Cancer Advocacy Network (BCAN) to create an unique education series for urology and oncology...
Using standard therapeutic regimens for patients with myasthenia gravis (mGM) is often complicated by multiple comorbidities. New targeted agents may lessen treatment burdens. To address these challenges, PlatformQ Health, the National Organization for Rare Disorders, and the Myasthenia Gravis Foundation of America produced online continuing medical education for health care...
Primary mitochondrial disease (PMD) is often missed by clinicians due to the broad range of clinical presentations and genetic etiologies. Our recent program "Progressive Myopathy: Could it be a Genetic Mitochondrial Disease?" focused on diagnosing this condition in infants, children, and adults who present with progressive muscle weakness; understanding the...
The 2022 ASCO Annual Meeting is a place where cutting-edge research spanning all major disease sites comes together so leaders in the field can stay up-to-date on clinical trials, the latest findings, and global perspectives on oncology innovations. We are especially excited to have two accepted e-abstracts at the 2022 ASCO...
Digital Education Tackles Competency Gaps in Understanding Gene and Cell Therapy The proliferation of gene and cell therapies is transforming medical care for many previously untreatable conditions. This brings a steep learning curve for clinicians seeking to understand the science, identify and counsel patients who are good candidates for this...
Aligned Education Fosters Better Understanding Between Patients and Providers Download the E-Poster here. The 2022 American Society of Pediatric Hematology/Oncology (ASPHO) Conference brings together hematology/oncology professionals for premier education and networking. We're pleased to share that the conference has accepted our poster abstract "Impact of Patient-Provider Initiative on Treatment of...
Researchers from around the world will soon convene at the SITC Tumor Immune Microenvironment: A Holistic Approach to explore the latest breakthroughs in immunotherapy. PlatformQ Health is pleased to be presenting a poster at the event highlighting impressive outcomes from its recent CME program "Incorporating Checkpoint Inhibitors into Cancer Care:...
Poster Presentation The Power of Education to Debunk Myths and Misconceptions about Clinical Trial Participation Among People with Diverse Racial and Ethnic Backgrounds The 2022 Alliance Industry Summit (ASI) will feature our poster about the power of education to debunk myths and misconceptions about clinical trial participation among people from...
Aligned Education Improves Patient Outcomes Across CME Programs The American Academy of Neurology's Annual Conference kicks off on April 2, 2022 in Seattle, featuring exclusive neurology science and education. We're pleased to share that PlatformQ Health has three posters published at the event, highlighting the outcomes of three aligned patient/provider...
Immune checkpoint inhibitors have brought tailored treatments for patients with a variety of cancers. This is changing the face of treatment and the practice patterns clinicians have for everything from diagnosis to testing, adverse event management, and survivorship care. To help clinicians prepare for these changes, PlatformQ Health and the...